New targeted pill challenges chemo in major lung cancer trial
NCT ID NCT06281964
Summary
This study is comparing a new oral drug, PLB1004, to standard platinum-based chemotherapy for people with advanced non-small cell lung cancer (NSCLC) that has a specific genetic change called an EGFR exon 20 insertion. The main goal is to see if PLB1004 is better at controlling the cancer and delaying its progression. It is for adults who have not yet received any treatment for their advanced cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangzhou, 510080, China
Conditions
Explore the condition pages connected to this study.